CD3E
T-cell surface glycoprotein CD3 epsilon chain
As of the edition of 20 October 2026, CD3E (T-cell surface glycoprotein CD3 epsilon chain, UniProt P07766) has 23 drugs tested at it and 13 companies on the list, 4 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P07766
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 44
- Disease areas
- Cancer; Immune system; Blood and lymph; Heart and blood vessels; Infections; Nutrition and metabolism; Hormones; Lungs and airways
- Registered trials of its drugs
- 657
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 13 |
| Active | 1 |
| Went quiet | 2 |
| Stopped | 7 |
| Total | 23 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Blinatumomab | Marketed | Phase 4 | Ends 2031 |
| Glofitamab | Marketed | Phase 4 | Ends 2035 |
| Epcoritamab | Marketed | Phase 3 | Ends 2035 |
| Teclistamab | Marketed | Phase 4 | Ends 2034 |
| Elranatamab | Marketed | Phase 4 | Ends 2035 |
| Mosunetuzumab | Marketed | Phase 3 | Ends 2034 |
| Talquetamab | Marketed | Phase 4 | Ends 2035 |
| Tarlatamab | Marketed | Phase 3 | Ends 2036 |
| Linvoseltamab | Marketed | Phase 4 | Ends 2037 |
| Teplizumab | Marketed | Phase 4 | Ends 2034 |
| Muromonab-cd3 | Marketed | Phase 3 | Ended 2004 |
| Odronextamab | Marketed | Phase 3 | none listed |
12 of 23 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 1 |
| Undetermined | 8 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| Sanofi | Route B |
| GSK | Route A |
| Virogen Biotechnology | Route A |
The other 10 companies at CD3E
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at CD3E, ranked, with the facts behind eachRequest access. Nothing is shown until you do.